NERV (Minerva Neurosciences) Moat Score: 2/10 (As of Jun. 29, 2026)


NERV Minerva Neurosciences Inc NERV
32 GF Score
Price $4.38
! 1 Warning Sign
View Full Analysis

What is Minerva Neurosciences Moat Score?

Minerva Neurosciences NERV +6.59% 32 Moat Score is 2 as of Jun. 29, 2026. GuruFocus rates NERV with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,401 Biotechnology companies, Minerva Neurosciences ranks better than 58.1% on this metric.

Minerva Neurosciences has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Minerva Neurosciences has No Moat: Minerva Neurosciences operates in the biotech sector with limited market presence and no significant IP or regulatory advantages. It lacks strong brand strength, customer loyalty, or a superior distribution network, leading to a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Minerva Neurosciences might have No Moat - Very weak/transient advantages.

Minerva Neurosciences  (NAS:NERV) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Minerva Neurosciences Moat Score Related Terms

NERV vs TTRX, WHWK, IMUX: Moat Score Comparison

For the Biotechnology subindustry, Minerva Neurosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minerva Neurosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Moat Score falls into.


NERV
32GF Score
Minerva Neurosciences Inc NERV
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Minerva Neurosciences (NERV) has a Moat Score of 2 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Minerva Neurosciences ranks #587 out of 1401 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Minerva Neurosciences' Moat Score too high?
Minerva Neurosciences' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Minerva Neurosciences' value of 2 is 0% at this industry median. Based on the distribution chart, Minerva Neurosciences ranks #587 out of 1401 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Minerva Neurosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Minerva Neurosciences' Moat Score compare to TTRX and WHWK?
According to the Biotechnology industry distribution chart, Minerva Neurosciences ranks #587 out of 1401 companies for Moat Score. This puts Minerva Neurosciences in the upper half of its industry. The industry median Moat Score is 2.00. Minerva Neurosciences' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minerva Neurosciences's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minerva Neurosciences's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Neurosciences stock overvalued right now?
Minerva Neurosciences (NERV) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Minerva Neurosciences' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Minerva Neurosciences (NERV), the current Moat Score is 2 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Neurosciences Business Description

Other Exchanges 4MNA:Germany
Address 1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
32GF Score

Get the complete analysis for NERV

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.38
Price